BMO Capital analyst Kostas Biliouris initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $50 price target The firm ...

Bank of Montreal’s consistently bullish chief investment strategist isn’t blinking as U.S. President Donald Trump’s tariff ...

BMO Capital initiated coverage of Rocket Pharmaceuticals (RCKT) with an Outperform rating and $50 price target The gene therapy company has “two major differences from the typical gene therapy stories ...

Fintel reports that on February 26, 2025, BMO Capital upgraded their outlook for Ingevity (NYSE:NGVT) from Market Perform to ...

U.S. government debt rallied aggressively overnight and into Tuesday’s trading session, pushing yields below key technical ...

BMO Capital lowered the firm’s price target on First Solar (FSLR) to $230 from $260 but keeps an Outperform rating on the ...

FN opened at C$40.75 on Thursday. The firm’s fifty day moving average is C$40.44 and its two-hundred day moving average is C$40.34. The firm has a market cap of C$2.45 billion, a PE ratio of 13. ...

BMO Capital analyst Brian Pitz raised the firm’s price target on eBay (EBAY) to $63 from $59 and keeps a Market Perform ...

Whiplash from continually changing developments on tariffs has lashed investor sentiment, said Douglas Porter, chief economist at BMO Capital Markets, who noted stocks have been pressured for most of ...

Evertz Technologies (TSE:ET – Free Report) had its price target reduced by BMO Capital Markets from C$15.00 to C$13.50 in a research report report published on Thursday,BayStreet.CA reports.

Bank of Montreal beat estimates as it benefited from strong performance in its capital-markets business and set aside less money than expected to cover possible loan losses. The Canadian bank ...